ZLNA — Zelluna ASA Share News
0.000.00%
Last trade - 00:00- NOK544.15m
- NOK451.38m
Brief: Ultimovacs Announces Positive Three-Year Results In Cohort 1 Of UV1-103 Study In Metastatic Malignant Melanoma
Brief: Ultimovacs Receives US Patent And Trademark Office Notice Of Allowance
Brief: Ultimovacs Q2 Oper Loss Narrows To NOK 35.4 Mln
Brief: Ultimovacs Expands High Dose Cohort Size In Tendu Phase I Prostate Cancer Trial
Brief: Ultimovacs’ UV1 Cancer Vaccine Shows Strong Overall Survival In Malignant Melanoma Phase I Trial
Brief: Ultimovacs Q1 Operating Loss At NOK 31.9 Million
Brief: Ultimovacs Provides Results From Testing Of UV1
Brief: Ultimovacs Announces Publication In The Journal Of Translational Medicine On Mechanistic Rationale Of Uv1 Cancer Vaccine Supporting Phase 2 Study Design In Malignant Mesothelioma
Brief: Ultimovacs Says Uv1 In Combination With Pembrolizumab Shows 60% Objective
Brief: Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology
Brief: Ultimovacs Q1 Operating Loss Narrows To NOK 31.2 Million
Brief: Ultimovacs Starts Clinical Evaluation Of Novel Tet-Platform
Brief: Ultimovacs Q4 Operating Loss Narrows To NOK 25.6 Mln
Brief: Ultimovacs ASA - Announces Positive 5-Year Overall Survival Update
Brief: Ultimovacs Q3 Operating Loss Widens To NOK 31.1 Million
Brief: Ultimovacs Announces Updated Positive Results From Phase I Trial
Brief: Ultimovacs Announces Positive Topline Results From Phase I Combination Trial Evaluating Universal Cancer Vaccine, Uv1, In Malignant Melanoma Patients
Brief: Ultimovacs H1 Oper Loss Widens To NOK 36.2 Mln
Brief: Ultimovacs Contemplates Private Placement